Caroline Stark Beer, M.B.A., serves as Chief Business Officer at Sionna Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapies for cystic fibrosis (CF). In this pivotal role, she leads all business development, strategic partnerships, licensing, and corporate strategy efforts, positioning Sionna to advance its pipeline of CFTR modulators from preclinical stages through clinical development and potential commercialization. Her strategic oversight has been instrumental in forging key alliances and securing funding to accelerate Sionna's mission of addressing unmet needs in CF treatment. With over 20 years of experience in the biopharmaceutical industry, Caroline previously held senior leadership positions at Vertex Pharmaceuticals, where she directed global business development and alliance management for the company's CF franchise, contributing to landmark deals exceeding $1 billion in value. Earlier in her career, she served as Vice President of Business Development at a mid-sized biotech firm, successfully negotiating multiple co-development and licensing agreements that advanced therapies to market. Her track record includes driving revenue growth, optimizing portfolio strategies, and navigating complex regulatory landscapes, earning her recognition as a top executive in biotech dealmaking. Caroline holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in Biology from Duke University. A sought-after speaker on biotech innovation and partnerships, she is passionate about translating scientific breakthroughs into patient impact, particularly for rare diseases like CF. Under her leadership, Sionna continues to build a robust ecosystem of collaborators to deliver transformative medicines.